IL17A and postmenopausal osteoporosis: Based on the network pharmacological analysis of the target pathway of Liuwei Dihuang pills, it may inhibit the inflammatory response and oxidative stress by acting on the pro-inflammatory cytokines IL-1, IL-6, interleukin-17 (IL-17), and the FoxO1 signaling pathway, thereby treating postmenopausal osteoporosis (Qingchan et al., 2022).